FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)

Metastatic Colorectal Cancer Clinical Trial

— VOLFI  

Official title:

An Open-label 2:1 Randomized Phase II Study of Panitumumab Plus FOLFOXIRI or FOLFOXIRI Alone as First-line Treatment of Patients With Non-resectable Metastatic Colorectal Cancer and RAS Wild Type

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01328171
• Other study ID #: AIO KRK 0109
• Secondary ID: 2009-017731-17
• Status: Completed
• Phase: Phase 2
• Start date: April 2011
• Est. completion date: January 2022

Study information

• Verified date: June 2023
• Source: AIO-Studien-gGmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer of RAS wildtype. The patients will be treated in two therapy groups:

Experimental arm A: Chemotherapy with FOLFOXIRI + panitumumab Standard arm B: Chemotherapy with FOLFOXIRI

Recruitment information / eligibility

• Status: Completed
• Enrollment: 93
• Est. completion date: January 2022
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Cohort I: Histologically confirmed and definitively inoperable or irresectable metastatic colorectal cancer. Focus on patients with large tumor load at metastatic sites and/or symptomatic metastatic disease

• Cohort II: Chance of secondary resection with curative intent defined and reviewed by expert panel

• Adult patients (= 18 years of age)

• RAS wild-type tested in

• KRAS exon 2 (codons 12/13)

• KRAS exon 3 (codons 59/61)

• KRAS exon 4 (codons 117/146)

• NRAS exon 2 (codons 12/13)

• NRAS exon 3 (codons 59/61)

• NRAS exon 4 (codons 117/146) assessed by an institution participating in and certified by the specific working group of the Deutsche Gesellschaft für Pathologie)

• At least one measurable lesion according to RECIST measured within 3 weeks prior to registration

• No previous chemotherapy for metastatic disease (adjuvant chemotherapy for non-metastatic disease is allowed if terminated more than 6 months ago)

• Performance status ECOG 0-1

• Male and female subjects > 18 years of age

• Adequate haematological, hepatic, renal and metabolic function parameters:

Leukocytes > 3000/mm³, ANC = 1500/mm3, platelets = 100,000/mm3, Hb > 9g/dl (may be transfused or treated with erythropoietin to maintain or exceed this level)Creatinine clearance = 50 ml/min or serum creatinine = 1.5 x upper limit of normal Bilirubin = 1.5 x upper limit of normal, GOT-GPT = 2.5 x upper limit of normal in absence of liver metastases, or = 5 x upper limit of normal in presence of liver metastases, AP = 5 x upper limit of normal Magnesium = lower limit of normal; calcium = lower limit of normal (may be substituted to maintain or exceed this level)

• Negative pregnancy test and willingness to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment (adequate: oral contraceptives, intrauterine device or barrier method in conjunction with spermicidal jelly).

• Before subject registration, written informed consent must be given according to ICH-GCP, and national/local regulations.

Exclusion Criteria:

• Past or current history of malignancies except for the indication under this study and curatively treated:

• Basal and squamous cell carcinoma of the skin

• In-situ carcinoma of the cervix

• Other malignant disease without recurrence after at least 5 years of follow-up

• Clinically significant cardiovascular disease in (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) = 6 months before enrolment.

• Clinically relevant interstitial lung disease, e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.

• History of evidence upon physical examination of CNS disease unless adequately treated (e.g. primary brain tumour, seizure not controlled with standard medical therapy, brain metastases or history of stroke).

• Pre-existing neuropathy > grade 1 (NCI CTCAE), except for loss of tendon reflex

• Allogeneic transplantation requiring immunosuppressive therapy.

• Severe non-healing wounds, ulcers or bone fractions.

• Evidence of bleeding diathesis or coagulopathy.

• Patients not receiving therapeutic anticoagulation must have an INR < 1,5 ULN and aPTT < 1,5 ULN within 7 days prior to randomization. The use of full dose anticoagulants is allowed as long as the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least two weeks at the time of randomisation.

• Concomitant therapy with certain anti-viral medicines (sorivudine and brivudine or analogue compounds).

• Major surgical procedure, open biopsy, nor significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study except for surgery for colorectal cancer with curative intent and central venous line placement for chemotherapy administration.

• Pregnancy or breastfeeding women.

• Subjects with known allergy to the study drugs or to any of its excipients.

• Known DPD deficiency.

• Current or recent (within the 28 days prior to starting study treatment) treatment of another investigational drug or participation in another investigational study.

• Known grade III/IV allergic reaction against monoclonal antibodies.

• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before registration in the trial.

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Metastatic Colorectal Cancer

Intervention

Drug:
• FOLFOXIRI + Panitumumab
irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3000 mg/m² cont. inf. + panitumumab, iv, 6 mg/kg BW all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
• FOLFOXIRI
irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles

Locations

Country	Name	City	State
Germany	Klinikum Augsburg	Augsburg	Bayern
Germany	Klinikum Esslingen	Esslingen	Baden-Württemberg
Germany	Klinikum der J.W. Goethe-Universität Frankfurt	Frankfurt	Hessen
Germany	Franziskus Hospital Niels-Stensen-Kliniken Klinik für Internistische Onkologie und Hämatologie	Georgsmarienhütte	Niedersachsen
Germany	Universitätsklinikum Halle	Halle	Sachsen-Anhalt
Germany	SLK-Kliniken Heilbronn GmbH	Heilbronn	Baden-Württemberg
Germany	Universitätsklinikum Jena	Jena	Thüringen
Germany	Ortenau Klinikum	Lahr	Baden-Württemberg
Germany	Klinikum Ludwigsburg	Ludwigsburg	Baden-Württemberg
Germany	Universitätsklinikum Mannheim	Mannheim	Baden-Württemberg
Germany	Universitätsklinikum Gießen und Marburg GmbH	Marburg	Hessen
Germany	Klinikum Schwäbisch Gmünd	Mutlangen	Baden-Württemberg
Germany	Kreiskliniken Esslingen gGmbH Klinik Nürtingen	Nürtingen	Baden-Württemberg
Germany	Marienhospital Osnabrück Niels-Stensen-Kliniken Klinik für Innere Medizin	Osnabrück	Niedersachsen
Germany	St. Vincenz-Krankenhaus	Paderborn	Nordrhein-Westfalen
Germany	Leopoldina-Krankenhaus der Stadt Schweinfurth gGmbH	Schweinfurt	Bayern
Germany	Schwerpunktpraxis und Tagesklinik Onkologie Hämatologie Gastroenterologie Palliativmedizin Drs. Höring, Respondek, Schwinger, Thunert	Stuttgart	Baden-Württemberg
Germany	Klinikum Mutterhaus der Borromäerinnen gGmbH	Trier	Rheinland-Pfalz
Germany	Universitätsklinikum Ulm Zentrum für Innere Medizin	Ulm	Baden-Württemberg

Sponsors (3)

Lead Sponsor	Collaborator
AIO-Studien-gGmbH	Amgen, ClinAssess GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	overall response rate	RECIST	up to about 6 month
Secondary	overall response rate in each cohort	RECIST	up to about 6 month
Secondary	secondary resection rate with curative intent for patients cohort I		up to about 6 month
Secondary	pathological response in liver surgery specimen	metrics: Pathological complete response (pCR): no residual cancer cells;major response (pPR): 1% to 49% residual cancer cells remaining; minor response (pMR): 50% to 99% residual cancer cells remaining; no response (pNR): 100% residual cancer cells remaining	up to about 6 month
Secondary	disease control rate	CR + PR + SD rate according to RECIST	up to about 6 month
Secondary	progression free survival		From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years
Secondary	duration of response	analyzed for responders only	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years
Secondary	time to response		up to about 6 month
Secondary	overall survival		From date of randomization until the date of death from any cause assessed up to 4 years
Secondary	time to recurrence (cohort II in case of secondary resection)		up to 4 years
Secondary	toxicity and feasibility	number of patients with adverse events and severity according to NCI CTC 3.0	up to about 6 month
Secondary	liver toxicity for resected patients (central histological review); biopsies should be obtained for all patients pre-treatment	histological findings according to CASH/SOS scores	up to 1 year
Secondary	QL (QLQ C30)	scores according to EORTC QLQ-C30 scoring manual (Quality of life)	Pre-treatment, before start of every 3rd cycle and at the end of treatment
Secondary	translational research (EGFR genetics and proteomics): prognostic and predictive impact on efficacy outcomes	Determination of EGFR mutations (exons 18, 19, 20, 21) in tumor tissue; determination of PIK3CA mutations (exon 9, 20) in tumor tissue; determination of EGFR, ERCC1, TS, MTHFR, OPRT, DHFR and CDKN polymorphism from normal and tumor tissue; determination of ERCC1, PTEN and TS protein expression in tumor tissue; epigenetic candidates; further exploratory studies such as miRNA analysis as approved by the AIO review board	up to 4 years

External Links

•   AIO-Homepage